title: The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.
abstract: BACKGROUND
  Therapeutic angiogenesis, if combined with primary percutaneous transluminal coronary angioplasty or stent placement, could improve the outcome of patients suffering from multifocal coronary disease.
  
  
  OBJECTIVE
  Because of the concern that angiogenic growth factors might promote restenosis, we studied the effect of a single intracoronary administration of recombinant fibroblast growth factor (rFGF)-2 on restenosis after balloon angioplasty and stent placement in a pig model of coronary atherosclerosis.
  
  
  METHODS
  In 24 Yucatan minipigs, coronary lesions were induced by arterial injury and 3 months of atherogenic diet. After 3 months, repeat catheterization was performed with balloon dilation or stent placement at the injured sites, with a follow-up of 6 weeks. Results were monitored using quantitative angiography, intravascular ultrasound (IVUS), and histomorphometry.
  
  
  RESULTS
  Intracoronary rFGF-2 2 microg/kg did not affect neointima formation or remodeling in this model. A small but significant aggravation of late lumen loss was observed in the reference segments of the rFGF-2-treated group. Angiographic and echographic late lumen loss, intimal hyperplasia, and arterial remodeling, as well as histologic neointima were all similar in the rFGF-2- and the vehicle-treated group. Confirming earlier studies from our group and those of others, stented arteries compared with balloon-dilated arteries had increased angiographic late lumen loss, a trend toward increased intimal hyperplasia and decreased remodeling.
  
  
  CONCLUSIONS
  We conclude that rFGF-2 does not aggravate restenosis after balloon dilation or stenting in this pig model of coronary atherosclerosis. Future combinations of angioplasty and therapeutic angiogenesis in a single session should be pursued as a feasible and safe strategy.
authors.affiliation: Dartmouth Medical School, Hanover, New Hampshire, USA. Mark.J.Post@Hitchcock.org
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Post
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Laham
authors.forename: Richard E
authors.initials: RE
authors.lastname: Kuntz
authors.forename: Deborah
authors.initials: D
authors.lastname: Novicki
authors.forename: Michael
authors.initials: M
authors.lastname: Simons
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001158:Arteries / Q000000981:diagnostic imaging / Q000187:drug effects / Q000601:surgery; D019917:Blood Vessel Prosthesis Implantation; D002404:Catheterization; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications* / Q000628:therapy*; D023903:Coronary Restenosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects / Q000601:surgery; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D007262:Infusions, Intravenous; D008297:Male; D008955:Models, Cardiovascular; D015607:Stents; D013552:Swine; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D016222:Fibroblast Growth Factor 2